Share ownership H. Lundbeck A/S

HLUN B

DK0061804770

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 13:02:26 17/04/2026 BST			5-day change	1st Jan Change
42.37 ^DKK	+1.51%		+4.85%	-1.90%

04-13	Lundbeck to present new neurology data at upcoming congress	FW
03-23	H. Lundbeck Price Target Down as AlphaValue/Baader Europe Expects Patent Expirations to Weigh on Growth	MT

Share class: H. Lundbeck A/S

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	796,592,888	266,877,323 ( 33.5 %)	4,164,817 ( 0.5228 %)	30.74 %
Stock B	10	199,148,222	39,236,567 ( 19.7 %)	348,816 ( 0.1752 %)

Major shareholders: H. Lundbeck A/S

Name	Equities	%	Valuation
Lundbeckfonden 66 %	525,751,306	66 %	3 235 M kr
Skagen AS 0.5321 %	4,239,000	0.5321 %	26 M kr
Sector Gamma AS 0.2552 %	2,033,195	0.2552 %	13 M kr
BNP Paribas Asset Management Belgium SA 0.1685 %	1,342,121	0.1685 %	8 M kr
Canaccord Genuity Wealth Ltd. 0.1594 %	1,269,997	0.1594 %	8 M kr
Nykredit Bank A/S (Investment Management) 0.1158 %	922,182	0.1158 %	6 M kr
Mackenzie Investments Corp. (United States) 0.0884 %	704,566	0.0884 %	4 M kr
Schroder Investment Management (Europe) SA (Finland) 0.0659 %	525,000	0.0659 %	3 M kr
AllianceBernstein Ltd. 0.048 %	382,224	0.048 %	2 M kr
Lars Bang 0.0452 %	360,328	0.0452 %	2 M kr
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Equities	%	Valuation
Lundbeckfonden 80 %	159,318,578	80 %	820 M kr
Nykredit Bank A/S (Investment Management) 0.4034 %	803,340	0.4034 %	4 M kr
Sparinvest SA (Denmark) 0.1058 %	210,671	0.1058 %	1 M kr
Equinor Asset Management ASA 0.0527 %	105,000	0.0527 %	540 753 kr
Niche Asset Management Ltd. 0.0461 %	91,744	0.0461 %	472 484 kr
Lars Bang 0.0452 %	90,082	0.0452 %	463 925 kr
Dorothea Wenzel 0.0226 %	45,000	0.0226 %	231 751 kr
AL Sydbank A/S (Investment Management) 0.0164 %	32,745	0.0164 %	168 638 kr
Johan Luthman 0.0131 %	26,049	0.0131 %	134 153 kr
Research Affiliates LLC 0.0032 %	6,373	0.0032 %	32 821 kr
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Other	86.01%
Institutional	2.05%
Individuals	0.11%
Unknown	11.83%

Based on 1000 largest holdings

Geographical origin of shareholders

Denmark	86.26%
Norway	0.84%
United Kingdom	0.32%
Belgium	0.17%
United States	0.11%
Individuals	0.11%
Finland	0.08%
Germany	0.05%
Switzerland	0.04%
Cyprus	0.04%
Liechtenstein	0.03%
France	0.03%
Austria	0.02%
Canada	0.02%
Luxembourg	0.01%
Sweden	0.01%
Italy	0.01%
Spain	0.01%
Estonia	0.01%

Based on 1000 largest holdings

H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimerâ€™s disease, Bipolar disorder, depression, epilepsy, Huntingtonâ€™s disease, Parkinsonâ€™s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimerâ€™s disease, Azilect for the treatment of Parkinsonâ€™s disease, Xenazine for the treatment of Huntingtonâ€™s disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.

Employees

5,039

Sector

Pharmaceuticals

Calendar

05-13 - Earnings release - Q1 2026

More about the company